UC Santa Barbara Students Get Bexsero to Treat Meningitis B - - BioPharm International

ADVERTISEMENT

UC Santa Barbara Students Get Bexsero to Treat Meningitis B



Novartis reported that its meningococcal serogroup B (MenB) vaccine, Bexsero (Meningococcal Group B Vaccine), will be used as part of a vaccination program at the University of California Santa Barbara (UCSB). In the last three months, FDA has approved the use of Bexsero twice in response to MenB outbreaks at US college campuses. More than 5,000 students were vaccinated at Princeton University and 20,000 students will be offered vaccination at UCSB.
 
Bexsero is the only licensed broad coverage vaccine approved in Europe, Canada, and Australia to help protect against invasive meningococcal disease caused by serogroup B. It was approved for use in the US under a treatment Investigational New Drug designation.
 
Source: Novartis

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
Author Guidelines

Click here